Nevertheless, S100A4‐positive stage II colon cancer patients randomized to adjuvant 5‐fluorouracil and levamisole had a poor outcome with an estimated 3‐year relapse‐free survival of 71% compared to 88% for S100A4‐negative patients (Fig. S3E). This evidence concerns the gene S100A4 and malignant colon neoplasm.